JacobusJW schreef op 2 april 2018 19:50:
[...]
In het 2017 jaarverslag, BLZ 16/24;
The company is developing a new very small injection version of the full dose of Ruconest which can be used for intravenous (in ader), intramuscular (in spier) or subcutaneous (onderhuids) delivery.
We now have a good formulation of Ruconest suitable for these purposes and are filling this for direct approval as an alternate form of Ruconest intravenous treatment.
The new form of Ruconest will thus be available on approval for intravenous administration, where it will be quicker and easier, but will need to be tested in some clinical settings for intramuscular and subcutaneous delivery, and this clinical testing program is now expected to start in the second half of 2018.
The program is slightly behind schedule because of the need to divert Ruconest production to cover shortfalls of competitor products in late 2017.
We are also exploring other routes of administration which are NOT injection-based and so are not painful at all.